Home
Explore services
Integrated solutions
Data & analytics
Tailored Reporting
Strategy & consulting
AI
Industry focus
Enterprise, mid-market & emerging pharmaceutical
Biotechnology
Financial Institutions
Education
Professional services
How we help
Pricing strategy & market access
Health technology assessment
Regulatory compliance
Commercial strategy & launch planning
Contact us
Responsive Menu
Home
Explore services
▼
Integrated solutions
Data & analytics
Tailored Reporting
Strategy & consulting
AI
Industry focus
▼
Enterprise, mid-market & emerging pharmaceutical
Biotechnology
Financial Institutions
Education
Professional services
How we help
▼
Pricing strategy & market access
Health technology assessment
Regulatory compliance
Commercial strategy & launch planning
Contact us
LOGIN
Blogs
The growing call for greater transparency into drug prices Guest writer: Kyle Forcier, Model N
20 May 2022
Read More
FDA deals significant blow to low-priced Chinese oncology drugs
6 April 2022
Read More
Women Scientists behind the COVID-19 vaccines
8 March 2022
Read More
Canada’s PMPRB drug pricing reforms face additional legal challenges
By Margaret Labban, PhD
24 February 2022
Read More
Growing number of US states enacting legislation to lower drug prices
By Margaret Labban, PhD
15 February 2022
Read More
NICE’s latest reform – why was it needed and what does it mean for innovation?
By Sevcan Cigerli
28 January 2022
Read More
China issues 2021 national reimbursement drugs list, three key trends…
23 December 2021
Read More
Build Back Better could set new precedent for US drug pricing controls
By Margaret Labban, PhD
3 December 2021
Read More
10 steps for a successful market access strategy
20 September 2021
Read More
GPI horizon, the price forecasting methodology that is transforming market access strategy
27 August 2021
Read More
« Previous
1
2
3
Next »
Yearly Archives
2025
2024
2023
2022
2021
Stay Informed
Sign up to receive the latest news and trends
straight into your inbox from GPI